{"Clinical Trial ID": "NCT00671918", "Intervention": ["INTERVENTION 1:", "Attempted treatment", "Participants received a single 50 \u03bcg dose of radiolabelled Lymphoseek with 0.5 or 1.0 mCi Tc 99m and blue dye for lymphatic mapping and surgical resection of lymph nodes."], "Eligibility": ["Incorporation criteria:", "The patient gave his or her informed written consent with the permission of HIPAA before participating in the study, as well as his or her responsible caregiver, if applicable.", "The patient is a candidate for surgery, with the mapping of the lymph nodes being part of the surgical plan.", "The patient is at least 18 years of age at the time of consent.", "The patient has an ECOG performance status of grade 0 - 2 [8].", "The patient has a negative clinical status at the time of entry into the study.", "In the case of children of childbearing potential, the patient underwent a negative pregnancy test within 72 hours prior to administration of Lymphoseek, was surgically sterilized or was menopause for at least 1 year.", "At present, the patient is not involved in another study of experimental drugs.", "Melanoma Patients", "The patient has a diagnosis of primary melanoma.", "Patients with breast cancer", "The patient has a diagnosis of primary breast cancer.", "Patients with in situ channel carcinoma (CDIS) or non-invasive carcinoma if lymph node biopsy is part of the surgical plan.", "- Exclusion criteria:", "The patient is pregnant or breast-feeding;", "The patient has clinical or radiological signs of metastatic cancer, including abnormal or voluminous lymph nodes (i.e., all patients should be any T,N0,M0);", "The patient has a known hypersensitivity to Lymphazurine or Blue V patent.", "Melanoma Patients", "The patient has a Breslow depth of less than 0.75 mm;", "Patients who have undergone pre-operative chemotherapy, immunotherapy or radiotherapy;", "- Patients diagnosed with an anterior invasive melanoma that would occur in the same body region or potentially draining to the same nodal basin or patients with a trunk or end primary melanoma that has already had breast cancer potentially draining to the same axillary nodal basin;", "Patients who have undergone nodal pelvic surgery, regardless of type or radiation, in the nodal basin(s) that may drain primary melanoma;", "* Patients who have undergone extensive excision for primary melanoma (>1 cm in size) or complex reconstruction (rotation, free flap or skin graft of any type).", "Patients with breast cancer", "The patient has bilateral primary breast cancers or multiple tumours in her breast;", "Patients who have already undergone surgical procedures such as breast implants, reduction mammoplasty or axillary surgery;", "Patients undergoing bilateral mastectomy for any reason;", "Patients with pre-operative radiotherapy in the breast or axil affected"], "Results": ["Performance measures:", "- Concordance of blue dye and lymphoseek", "The proportion of lymph nodes detected intraoperatively by blue dye was also detected by Lymphoseek.", "Time limit: Surgery after injection of Lymphoseek and blue dye", "Results 1:", "Title of arm/group: Intention to deal with", "Description of the arm/group: Participants received a single dose of 50 \u03bcg of radiolabelled lymphoseek with 0.5 or 1.0 mCi Tc 99m and blue dye for lymphatic mapping and surgical resection of lymph nodes.", "Total number of participants analysed: 136", "Total number of units analysed", "Type of units Analysis: Lymph nodes Type of measurement: NumberNumber (95% confidence interval)Unity of measurement: Proportion of lymph nodes: 0.9767 (0.9466 to 0.9924)"], "Adverse Events": ["Undesirable Events 1:", "Total: 4/179 (2.23 per cent)", "Myocardial infarction [1]1/179 (0.56%)", "Nausea [1]1/179 (0.56%)", "- Vomiting [1]1/179 (0.56%)", "Cellulite [1]1/179 (0.56%)", "Changed radical mastectomy [1]1/179 (0.56%)"]}